Table 1. Patient characteristics.
| Characteristic | Total (n=103), n (% or range) | Salvage-SBRT (n=51), n (% or range) | Adjuvant-SBRT (n=52), n (% or range) | P |
|---|---|---|---|---|
| Male | 73 (70.9) | 39 (76.5) | 33 (63.5) | 0.15 |
| Median age (year) | 62 [42–83] | 63 [42–82] | 61.5 [42–83] | 0.519 |
| Performance status | ||||
| ECOG 0 | 48 (46.6) | 25 (49.0) | 23 (44.2) | 0.743 |
| ECOG 1 | 50 (48.5) | 23 (45.1) | 27 (51.9) | |
| ECOG 2 | 5 (4.9) | 3 (5.9) | 2 (3.8) | |
| Etiology | ||||
| HBV | 8 (7.8) | 4 (7.8) | 4 (7.7) | 0.427 |
| HCV | 68 (66.0) | 34 (66.7) | 34 (65.4) | |
| Alcohol | 9 (8.7) | 5 (9.8) | 4 (7.7) | |
| NASH | 6 (5.8) | 5 (9.8) | 1 (1.9) | |
| Mixed/other | 13 (12.6) | 3 (5.9) | 10 (19.2) | |
| Median size (cm) | 3 (1.2–9.4) | 3.4 (1.4–9.4) | 2.7 (1.2–8) | 0.912 |
| Median AFP (ng/mL) | 15.4 (1.6–12,976) | 15.9 (2.4–12,796) | 14.4 (1.6–7,765) | 0.305 |
| Child-Turcotte-Pugh score | ||||
| A | 61 (59.2) | 25 (49.0) | 32 (61.5) | 0.456 |
| B | 39 (37.9) | 23 (45.1) | 18 (34.6) | |
| C | 2 (1.9) | 0 (0) | 2 (3.8) | |
| AJCC tumor stage | ||||
| T1 | 42 (40.8) | 17 (33.3) | 25 (48.1) | 0.365 |
| T2 | 54 (52.4) | 27 (52.9) | 25 (48.1) | |
| T3 | 6 (5.8) | 4 (7.8) | 2 (3.8) | |
| T4 | 1 (1.0) | 1 (2.0) | 0 (0) | |
| BCLC stage | ||||
| A | 31 (30.1) | 12 (23.5) | 19 (36.5) | 0.325 |
| B | 63 (61.2) | 34 (66.7) | 29 (55.8) | |
| C | 9 (8.7) | 5 (9.8) | 4 (7.7) | |
| Median number of TACEs to target lesion | 2 [1–7] | 2 [1–4] | 1 [1–7] | 0.104 |
| Median SBRT dose (Gy) | 40 [24–50] | 40 [24–50] | 40 [30–50] | 0.855 |
| Transplant | 32 (31.1) | 14 (27.5) | 18 (34.6) | 0.432 |
SBRT, stereotactic body radiation therapy; TACE, transarterial chemoembolization; BCLC, Barcelona Clinic Liver Cancer.